

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

10 Jun 2026

### Comparing the effect of sevelamer carbonate and sevelamer hydrochloride on blood level of phosphate, Ca, ph, bicarbonate and gastrointestinal complications in patients undergoing maintenance hemodialysis

#### Protocol summary

##### Study aim

Comparison of Sevelamer Carbonate and Sevelamer Hydrochloride Effects on the Level of Calcium, Phosphorus, PH, Bicarbonate and Gastrointestinal Complications in Patients Undergoing Maintenance Hemodialysis

##### Design

Twenty-two samples are included in each group based on the sample size calculated from the results of a pilot study (with a power of 80% and a type 1 error of 5%). Patients will be selected among those in Valiasr Hospital who are under hemodialysis and have entry conditions. Patients will be divided into two groups of intervention with Sevelamer Hydrochloride and Sevelamer carbonate by block randomization method and each participant will be assigned a code to hide the intervention group.

##### Settings and conduct

In this randomized clinical trial study, patients who undergoing Hemodialysis in Vali Asr Hospital, Zanjan, Iran will participate in the study. Data analyzer and patients will be blinded. blinding were carried out by coding same shape bottles for both drugs.

##### Participants/Inclusion and exclusion criteria

Patients who undergo three sessions each week for a period of four hours hemodialysis and have a blood phosphorus level greater than 5.5 mg / dL. Exclusion criteria: Patients who have not taken limited Phosphorus diet. Patients who lose their ability to do so during the study Patients who are absent from dialysis session Patients who break their access for some reason Patients who have taken the medication inappropriately Patients with a history of primary hyperparathyroidism or history of parathyroidectomy. Patients with a history of gastrointestinal diseases include peptic ulcer, reflux, and constipation Patients with a history of congestive heart failure (due to electrolyte imbalance) Patients with

chronic obstructive pulmonary disease (COPD) (due to acid and basis disorders).

##### Intervention groups

group 1: 800 mg Sevelamer Carbonate triple time daily with each meal for 1 month. group 2: 800 mg Sevelamer Hydrochloride triple time daily with each meal for 1 month.

##### Main outcome variables

Blood PH ; Calcium level of serum ; serum phosphorus level ; bicarbonate level of serum ; gastrointestinal complications of each drugs.

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20141016019554N13**  
Registration date: **2018-02-17, 1396/11/28**  
Registration timing: **retrospective**

Last update: **2018-02-17, 1396/11/28**

Update count: **0**

##### Registration date

2018-02-17, 1396/11/28

##### Registrant information

##### Name

Maryam Jameshorani

##### Name of organization / entity

Zanjan University of Medical Sciences

##### Country

Iran (Islamic Republic of)

##### Phone

00989126416972 00982433770805 ,

##### Email address

dr.shirinameshorani@zumc.ac.ir

**Recruitment status****Recruitment complete****Funding source****Expected recruitment start date**

2017-03-21, 1396/01/01

**Expected recruitment end date**

2017-12-21, 1396/09/30

**Actual recruitment start date**

2017-03-21, 1396/01/01

**Actual recruitment end date**

2017-12-21, 1396/09/30

**Trial completion date**

empty

**Scientific title**

Comparing the effect of sevelamer carbonate and sevelamer hydrochloride on blood level of phosphate, Ca, ph, bicarbonate and gastrointestinal complications in patients undergoing maintenance hemodialysis

**Public title**

Comparing the effect of sevelamer carbonate and sevelamer hydrochloride on blood level of phosphate, Ca, ph, bicarbonate and gastrointestinal complications in patients undergoing maintenance hemodialysis

**Purpose**

Supportive

**Inclusion/Exclusion criteria****Inclusion criteria:**

Patients who undergo dialysis three sessions each week for four hours each day. Their blood phosphorus level is higher than 5.5 mg / dL.

**Exclusion criteria:**

Patients who have not taken limited Phosphorus diet. Patients who lose their ability to participate during the study Patients who are absent from dialysis session Patients who break their access for some reason Patients who have taken the medication inappropriately. Patients with a history of primary hyperparathyroidism or history of parathyroidectomy. Patients with a history of gastrointestinal diseases include peptic ulcer, reflux, and constipation Patients with a history of congestive heart failure (due to electrolyte imbalance) Patients with chronic obstructive pulmonary disease (COPD) (due to acid and basis disorders).

**Age**

No age limit

**Gender**

Both

**Phase**

3

**Groups that have been masked**

- Participant
- Data analyser

**Sample size**Target sample size: **44**Actual sample size reached: **44****Randomization (investigator's opinion)**

Randomized

**Randomization description**

patients were randomized with block randomization method individually. First, patients are matched in terms of age, sex, and level of phosphorus and other variables listed in the criteria for entry and exit, in 4 blocks, each block containing 11 patients. randomization was done by sealed envelopes by a third blinded person who was not one of the researchers.

**Blinding (investigator's opinion)**

Single blinded

**Blinding description**

patients and data analyzer were unaware of the type of drugs. drugs were bottled in coded bottles with only the investigator knowing which code refers to which intervention.

**Placebo**

Not used

**Assignment**

Parallel

**Other design features****Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Ethics Committee of Zanjan University of Medical Sciences

**Street address**

Khorramshahr Street

**City**

Zanjan

**Province**

Zanjan

**Postal code**

4515613113

**Approval date**

2017-07-04, 1396/04/13

**Ethics committee reference number**

ZUMS.REC.1396.122

**Health conditions studied****1****Description of health condition studied**

Calcium, Phosphorus, PH, Bicarbonate and Gastrointestinal Complications in Hemodialysis Patients

**ICD-10 code**

N18.4

**ICD-10 code description**

Chronic kidney disease, stage 4 (severe)

**Primary outcomes****1****Description**

Blood Calcium

**Timepoint**

at beginning of intervention and 1 month later

**Method of measurement**

measurement will be carried out by hospital laboratory

**2**

**Description**

blood Phosphorus

**Timepoint**

at beginning of intervention and 1 month later

**Method of measurement**

measurement will be carried out by hospital laboratory

**3**

**Description**

Blood pH

**Timepoint**

at beginning of intervention and 1 month later

**Method of measurement**

measurement will be carried out by hospital laboratory

**4**

**Description**

Blood Bicarbonate levels

**Timepoint**

at beginning of intervention and 1 month later

**Method of measurement**

measurement will be carried out by hospital laboratory

**Secondary outcomes**

empty

**Intervention groups**

**1**

**Description**

Intervention group 1: 800 mg Sevelamer Carbonate triple time daily with each meal for 1 month

**Category**

Treatment - Drugs

**2**

**Description**

Intervention group 2: Sevelamer Hydrochloride 800 mg triple daily with each meal for 1 month

**Category**

Treatment - Drugs

**Recruitment centers**

**1**

**Recruitment center**

**Name of recruitment center**

Valiasr Hospital in Zanjan

**Full name of responsible person**

Bahareh Halisalimi

**Street address**

Dr. Shariati Street

**City**

Zanjan

**Province**

Zanjan

**Postal code**

4515777978

**Phone**

+98 24 3377 0801

**Email**

baharehajisalimi@yahoo.com

**Sponsors / Funding sources**

**1**

**Sponsor**

**Name of organization / entity**

Zanjan University of Medical Sciences

**Full name of responsible person**

Dr. Alireza Shoghli

**Street address**

Khorramshahr Street

**City**

Zanjan

**Province**

Zanjan

**Postal code**

4515413113

**Phone**

+98 24 3342 0677

**Email**

Shoghli@zums.ac.ir

**Grant name**

**Grant code / Reference number**

**Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Zanjan University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

empty

**Country of origin**

**Type of organization providing the funding**

Academic

**Person responsible for general inquiries**

**Contact**

**Name of organization / entity**

Zabol University of Medical Sciences

**Full name of responsible person**

Behrooz Fazeli

**Position**

Resident of Internal Medicine

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Internal Medicine

**Street address**

Shariati St., Valiasr Hospital

**City**

Zanjan

**Province**

Zanjan

**Postal code**

4515777978

**Phone**

+98 919 674 7560

**Email**

dr.behroozfazeli@zums.ac.ir

## Person responsible for scientific inquiries

**Contact**

**Name of organization / entity**

Zanjan University of Medical Sciences

**Full name of responsible person**

Behrooz Fazeli

**Position**

Resident of Internal Medicine

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Internal Medicine

**Street address**

Shariati St., Valiasr Hospital

**City**

Zanjan

**Province**

Zanjan

**Postal code**

4515777978

**Phone**

+98 919 674 7560

**Email**

Dr.behroozfazeli@gmail.com

## Person responsible for updating data

**Contact**

**Name of organization / entity**

Zanjan University of Medical Sciences

**Full name of responsible person**

Behrooz Fazeli

**Position**

Resident of Internal Medicine

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Internal Medicine

**Street address**

Shariati St., Valiasr Hospital

**City**

Zanjan

**Province**

Zanjan

**Postal code**

4515777978

**Phone**

+98 919 674 7560

**Email**

Dr.behroozfazeli@gmail.com

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

No - There is not a plan to make this available

**Justification/reason for indecision/not sharing IPD**

There is no further information

**Study Protocol**

Undecided - It is not yet known if there will be a plan to make this available

**Statistical Analysis Plan**

Undecided - It is not yet known if there will be a plan to make this available

**Informed Consent Form**

Undecided - It is not yet known if there will be a plan to make this available

**Clinical Study Report**

Undecided - It is not yet known if there will be a plan to make this available

**Analytic Code**

Undecided - It is not yet known if there will be a plan to make this available

**Data Dictionary**

Undecided - It is not yet known if there will be a plan to make this available